Date: June 29, 2022
Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST)
As of May 2022, there have been more than 500 million confirmed cases of COVID-19. Additionally, more than 5 billion people have received at least one dose of a COVID-19 vaccine. Immune responses to natural COVID-19 infections, including to the numerous variants and subvariants, and to the variety of available vaccines are unique.
Two years into the global COVID-19 pandemic, the role of serology testing to evaluate immune responses has not yet been defined. This webinar will explore the role of serology testing to assess immune status.
Bio-Rad SARS-CoV-2 products provide you and your laboratory with efficient new ways to quantitatively characterize immune responses.
- Understand how SARS-CoV-2 serology testing results correlate with individual immune responses to COVID-19 infections or vaccinations
- Understand the value of SARS-CoV-2 serology testing and potential role of quantitative assays in determining protection against COVID-19
- Review serological responses from SARS-CoV-2 variants with a new quantitative assay that can differentiate multiple neutralizing and binding antibodies within a single test
Webinars will be available for unlimited on-demand viewing after live event.